Therapeutics

Phenserine

Overview

Name: Phenserine
Therapy Type: Small Molecule (timeline)
Target Type: Cholinergic System (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Inactive)
Company: Annovis Bio, TorreyPines Therapeutics, Inc.

Background

Phenserine is a physostigmine analog that inhibits acetylcholinesterase. It has also been shown to inhibit Aβ production by reducing expression of APP (Klein, 2007; Venti et al., 2004; Utsuki et al., 2006).

Findings

Phenserine’s development was stopped after it failed to improve cognition or clinical measures in two Phase 3 trials (Sep 2005 news).

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

News Citations

  1. Investigational Drug Phenserine Fails

Paper Citations

  1. . Phenserine. Expert Opin Investig Drugs. 2007 Jul;16(7):1087-97. PubMed.
  2. . The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region. Ann N Y Acad Sci. 2004 Dec;1035:34-48. PubMed.
  3. . Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide. J Pharmacol Exp Ther. 2006 Aug;318(2):855-62. PubMed.

Further Reading

No Available Further Reading